LABT: the balance sheet

MyFinsight

Lakewood-Amedex Biotherapeutics Inc. (LABT)

For the quarter ending 2026-03-31, LABT has $196,343 in assets. $3,037,991 in debts. $11,709 in cash and cash equivalents.

Balance Sheets	2026-03-31
Cash and cash equivalents	11,709
Prepaid expenses and other current assets	38,917
Total current assets	50,626
Operating lease right-of-use asset	129,519
Property and equipment, net	8,066
Other assets	8,132
Total assets	196,343

Accounts payable	547,829
Accrued expenses and other current liabilities	594,723
Accrued interest related parties	139,100
Operating lease liability current portion	121,044
Notes payable related parties	1,625,000
Total current liabilities	3,027,696
Operating lease liability, net of current portion	10,295
Total liabilities	3,037,991
Convertible preferred stock, value-Series AConvertible Preferred Stock	659
Convertible preferred stock, value-Series BConvertible Preferred Stock	2,381
Common stock, 0.0001 par value, 125,000,000 shares authorized 7,043,330 issued and 6,995,469 outstanding at march 31, 2026 and december 31, 2025	704
Additional paid-in capital	51,579,029
Accumulated deficit	-54,274,421
Treasury stock, 47,861 shares, at cost, at march 31, 2026 and december 31, 2025	150,000
Total stockholders deficit	-2,841,648
Total liabilities and stockholders deficit	196,343

Unit: Dollar. Numbers labeled with * are estimated quarterly values.